Abstract
The prevalence of pituitary adenoma is of 1/1000 and has been fora long time underestimated. Prolactinomas represent the most frequent subtype (60%). From the mid eighties, their treatment is usually simple and efficient, allowing clinical, biological and tumoral control in most cases. However, management of carcinoma or resistant prolactinoma can be challenging. In these particular cases, a multimodal therapy approach is needed. Recently, progress in genetics of pituitary adenoma has allowed a better understanding and management of these particular cases. In consequence, genetic evaluation is recommended in FIPA (Familial Isolated Pituitary Adenoma) cases and in young patients with macroprolactinomas.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
